title: Monitoring of TNFR1, IL-2Rα, HGF, CCL8, IL-8 and IL-12p70 following HSCT and their role as GVHD biomarkers in paediatric patients.
abstract: No predictive factors are currently available to establish patient-specific GVHD risk. A panel of six serum cytokines (TNF receptor 1, IL-2 receptor alfa (IL-2Rα), hepatocyte growth factor (HGF), monocyte chemo-attractant protein-2, IL-8, IL-12p70) were monitored at established time points (days -1, +1, +7, +14, +21, +28 and +60) in 170 paediatric hematopoietic SCT (HSCT) recipients. We found that higher concentrations of IL-2Rα on days +14 and +21 together with HGF on days +14 and +21 were significantly associated at a higher probability of both grade II-IV GVHD (on day +14 it was: 60% vs 28%, P=0.007) and grade III-IV (on day +14 it was: 40% vs 15%, P=0.001). The higher IL-8 serum concentration on day +28 was associated with a lower probability of chronic GVHD being 4% vs 29% (P=0.01) for patients with higher vs lower IL-8 serum concentration. These findings were confirmed when the analysis was restricted to the the matched unrelated donor group. In conclusion, even if the serum cytokine levels were related to several variables associated with HSCT, we identified two cytokines as predictors of GVHD II-IV and III-IV, translating into a higher TRM risk (17% vs 3%, P=0.004).
authors.affiliation: Paediatric Onco-Hematology and Stem Cell Transplant Unit, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Piazza Polonia 94, Turin, Italy. massimo.berger@unito.it
authors.forename: M
authors.initials: M
authors.lastname: Berger
authors.forename: E
authors.initials: E
authors.lastname: Signorino
authors.forename: M
authors.initials: M
authors.lastname: Muraro
authors.forename: P
authors.initials: P
authors.lastname: Quarello
authors.forename: E
authors.initials: E
authors.lastname: Biasin
authors.forename: F
authors.initials: F
authors.lastname: Nesi
authors.forename: E
authors.initials: E
authors.lastname: Vassallo
authors.forename: F
authors.initials: F
authors.lastname: Fagioli
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000097:blood*; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood* / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D017228:Hepatocyte Growth Factor / Q000097:blood; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018664:Interleukin-12 / Q000097:blood; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D009369:Neoplasms / Q000097:blood* / Q000276:immunology / Q000601:surgery*; D011379:Prognosis; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D016207:Cytokines; D053645:Interleukin-2 Receptor alpha Subunit; D016209:Interleukin-8; D047888:Receptors, Tumor Necrosis Factor, Type I; D018664:Interleukin-12; D017228:Hepatocyte Growth Factor